ReGEN Biomedical and Demcon Announce New Partnership
Demcon and ReGEN Biomedical announce a collaboration, with Demcon becoming a shareholder. This partnership not only promises growth and innovation for both parties but also contributes to strengthening the regenerative medicine sector as a whole and achieving the common goal within RegMed XB: expediting the market entry of the latest therapies for chronically ill patients.
The collaboration between Demcon and ReGEN Biomedical, within the framework of the RegMed XB pilot factory, exemplifies the power of public-private partnerships. It is a promising step towards sustainable profitability, aligning with the objectives of the National Growth Fund. We look forward to the positive outcomes of this collaboration!
ReGEN Biomedical, along with the Smart Biomaterials Consortium, LUMC, NecstGen, and ICAT, forms the RegMed XB Pilot Factory. The Pilot Factory brings together all the expertise and infrastructure necessary to bring regenerative medicine solutions to the market and is co-funded by the National Growth Fund, which invests €20 billion in projects for long-term economic growth between 2021 and 2025
To learn more about this exciting collaboration and its potential impact, please read the full press release.
Latest news
- RegMed XB is awarded to be one of the selected programs by Health~Holland
- 2024 in Review: RegMed XB Highlights
- RegMed XB 3rd Annual Conference 2025
- Two new Supervisory Board members
- RegMed XB and Nakanoshima Qross signed a memorandum of understanding
- Three National Growth Fund-initiatives sign collaboration agreement